With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise.
The biotech sector is trading higher today, driven by a series of positive clinical trial results and regulatory updates from several companies. Vanda Pharmaceuticals reported successful Phase 3 data for its drug to prevent GLP-1-induced vomiting. Additionally, both AbbVie and Pfizer announced positive Phase 3 results and a regulatory submission for their respective multiple myeloma treatments. This news flow, combined with other positive study results, is boosting investor sentiment across the industry.